NICE has recommended mirvetuximab soravtansine for resistant ovarian cancer, citing better survival and a less burdensome treatment experience.

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

"Somewhere between 35-80% of people with PMOS experience insulin resistance, making weight management important." ...

Painful periods are often considered normal, but severe menstrual pain that interferes with daily activities, requires ...

We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...

For women with advanced high-grade serous ovarian cancer (OC), short-term fasting (STF) may enhance the efficacy of ...

Lemme, the award-winning wellness brand co-founded by Kourtney Kardashian Barker, introduces Lemme Balance Capsules, an ...

"One of the most amazing things I’ve ever seen," clinician-scientist Samuel Hume wrote alongside a video clip posted on X.

So much for great egg-spectations. Most women are born with an ovary on each side of their uterus. These almond-shaped glands produce and release eggs for fertilization and secrete the hormones ...

A £600 million tranche of government funding for a key part of the UK's life sciences strategy – expanding the country's ...

About one in eight women – or around 170 million people – globally are diagnosed with PCOS, and despite how common the ...

"If you are diagnosed with Polyendocrine Metabolic Ovarian Syndrome, it doesn't mean that you are destined to have poor ...